GlassScriptPhysician profile
Debra J Williams
NPI 1609870930
$1,452.47
in general payments reported to CMS, 2019-2025
24 companies · $19.23 in 2025
The $19.23 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $89.65 · 2021: $270 · 2022: $460 · 2023: $209 · 2024: $12.70 · 2025: $19.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $241.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.62 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Hologic Sales and Service, LLC | $226.13 | 2019-2025 | Fluent Fluid Management System, Novasure |
| Mayne Pharma Commercial LLC | $58.33 | 2022-2023 | |
| Therapeuticsmd, INC. | $57.60 | 2019-2022 | |
| Pfizer INC. | $49.06 | 2019-2023 | |
| Exeltis, USA INC. | $47.19 | 2021-2023 | Slynd |
| Millicent US INC | $39.07 | 2019-2020 | |
| Mylan Pharmaceuticals INC. | $37.84 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $35.92 | 2019 | |
| Evofem Biosciences, INC. | $33.69 | 2022 | |
| Organon LLC | $31.24 | 2021-2023 | Nexplanon |
| Lupin INC. | $27.71 | 2019-2021 | |
| Allergan, INC. | $26.91 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $22.32 | 2019 | |
| Astellas Pharma US INC | $22.27 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $18.22 | 2023 | Myfembree |
| Smith+Nephew, INC. | $16.70 | 2023 | Pico |
| Merck Sharp & Dohme LLC | $16.18 | 2019 | |
| Agile Therapeutics, INC. | $15.67 | 2021 | |
| Shield Therapeutics INC | $14.84 | 2023 | Accrufer |
| Avanos Medical | $14.10 | 2019 | |
| Duchesnay USA Incorporated | $12.73 | 2019 | |
| Meditrina | $12.70 | 2024 | |
| Avion Pharmaceuticals | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.